Citations

Showing 10 of 108162 citations.

Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
Chumsri, Saranya , Li, Zhuo , Serie, Daniel, Colón‐Otero, Gerardo , Pogue–Geile, Katherine L. , Gavin, Patrick G. , Paik, Soonmyung , Moreno‐Aspitia, Alvaro , Perez, Edith A. , Thompson, E. Aubrey , Serie, Daniel J, Mashadi-Hossein, Afshin , Song, Nan

Mayo Clinic

Journal of Clinical Oncology | October 17, 2019 | Volume: 37 | Issue: 35 | Pages: 3425-3435

10.1200/jco.19.00443 | PMID 31622131 Get It

PURPOSE Recent trials have shown potential benefit of extended adjuvant endocrine therapy and relatively high risk of recurrence (RoR) after 5 years in hormone receptor-positive (HR+) human epidermal growth factor receptor 2–negative (HER2−) breast cancer. Although risk of late relapse in HR+ HER2− breast cancer is fairly well defined, the risk in HER2-positive (HER2+) breast cancer treated with adjuvant trastuzumab-based chemotherapy remains largely unknown. METHODS We included 3,177 patients with HER2+ breast cancer treated with adjuvant chemotherapy alone or with trastuzumab from the North Central Cancer Treatment Group N9831 (ClinicalTrials.gov identifier: NCT00005970 ) and National Surgical Adjuvant Breast and Bowel Project B-31 (ClinicalTrials.gov identifier: NCT00004067 ) trials. RESULTS Overall, HR+ breast cancer was significantly associated with improved recurrence-free survival (RFS) during the first 5 years (hazard ratio, 0.65; 95% CI, 0.56 to 0.77; P < .001). Among patients treated with trastuzumab, cumulative hazard for RFS was lower in patients with HR+ HER2+ breast cancer during the first 5 years (10.96% v 17.48%; hazard ratio, 0.60; 95% CI, 0.45 to 0.79; P < .001). However, there was no significant difference in RFS based on HR status during years 5 to 10 (hazard ratio, 1.32; 95% CI, 0.93 to 1.88; P = .12). A comparable degree of trastuzumab benefit was observed in HR+ and HR− breast cancers ( P for interaction = .87). Furthermore, we observed low RoR in years 5 to 10 among patients with HR+ HER2+ breast cancer: 3.23% in patients without lymph node involvement (N0) and 6.39% in patients with involvement of one to three lymph nodes (N1). CONCLUSION The benefit of adjuvant trastuzumab persists for a long time. A distinct pattern of recurrence was observed between HR+ and HR− HER2+ disease but with similar degree of benefit from adjuvant trastuzumab. RoR in years 5 to 10 in HR+ HER2+ breast cancer is low, particularly in patients with N0 or N1 disease.
Vaping-Associated Lung Injury
Boland, Jennifer M. , Aesif, Scott W.

Mayo Clinic

American Journal of Clinical Pathology | October 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajcp/aqz191 | PMID 31651033 Get It

Structural and functional studies of TBC1D23 C-terminal domain provide a link between endosomal trafficking and PCH
Huang, Wenjie , Liu, Zhe , Yang, Fan , Zhou, Huan , Yong, Xin, Yang, Xiaoyu , Zhou, Yifei, Xue, Lijia, Liu, Dingdong, Meng, Wentong , Zhang, Wenming , Zhang, Xiaohu , Shen, Xiaofei , Li, Li , Ma, Cong , Billadeau, Daniel D. , Mo, Xianming , Jia, Da , Ma, Cong , Jia, Da , Yong, Xin, Zhang, Yihong, Zhang, Wenming, Sun, Qingxiang , Wei, Yuquan

Mayo Clinic

Proceedings of the National Academy of Sciences | October 17, 2019 | Volume: 116 | Issue: 45 | Pages: 22598-22608

10.1073/pnas.1909316116 | PMID 31624125 Get It

Pontocerebellar hypoplasia (PCH) is a group of neurological disorders that affect the development of the brain, in particular, the pons and cerebellum. Homozygous mutations of TBC1D23 have been found recently to lead to PCH; however, the underlying molecular mechanisms remain unclear. Here, we show that the crystal structure of the TBC1D23 C-terminal domain adopts a Pleckstrin homology domain fold and selectively binds to phosphoinositides, in particular, PtdIns(4)P, through one surface while binding FAM21 via the opposite surface. Mutation of key residues of TBC1D23 or FAM21 selectively disrupts the endosomal vesicular trafficking toward the Trans-Golgi Network. Finally, using the zebrafish model, we show that PCH patient-derived mutants, impacting either phosphoinositide binding or FAM21 binding, lead to abnormal neuronal growth and brain development. Taken together, our data provide a molecular basis for the interaction between TBC1D23 and FAM21, and suggest a plausible role for PtdIns(4)P in the TBC1D23-mediating endosome-to-TGN trafficking pathway. Defects in this trafficking pathway are, at least partially, responsible for the pathogenesis of certain types of PCH.
Acetaminophen induced methemoglobinemia
Sahu, Kamal Kant , Lal, Amos , George, Susan, Lal, Amos , Mishra, Ajay Kumar

Mayo Clinic

Clinical Toxicology | October 17, 2019 | Volume: 58 | Issue: 7 | Pages: 784-785

10.1080/15563650.2019.1677909 | PMID 31621426 Get It

Point-Counterpoint: Should We Be Performing Metagenomic Next-Generation Sequencing for Infectious Disease Diagnosis in the Clinical Laboratory?
Miller, Steve , Chiu, Charles Y. , Rodino, Kyle G. , Chiu, Charles , Miller, Melissa B.

Mayo Clinic

Journal of Clinical Microbiology | October 17, 2019 | Volume: 58 | Issue: 3 | Pages: No page available

10.1128/jcm.01739-19 | PMID 31619533 Get It

With established applications of next-generation sequencing in inherited diseases and oncology, clinical laboratories are evaluating the use of metagenomics for identification of infectious agents directly from patient samples, to aid in the diagnosis of infections. Metagenomic next-generation sequencing for infectious diseases promises an unbiased approach to detection of microbes that does not depend on growth in culture or the targeting of specific pathogens.
Submentalis Rapid Eye Movement Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy
McCarter, Stuart J. , Feemster, John, Tabatabai, Grace, Sandness, David J., Timm, Paul, McCarter, Allison R., Talley, Heather N., Junna, Mithri R. , Savica, Rodolfo , Benarroch, Eduardo E. , Josephs, Keith A. , Silber, Michael H. , Louis, Erik K. St. , Feemster, John C, Tabatabai, Grace M, Timm, Paul C, St Louis, E K , McCarter, Stuart J , Singer, Wolfgang , Coon, Elizabeth A. , Boeve, Bradley F.

Mayo Clinic

Annals of Neurology | October 17, 2019 | Volume: 86 | Issue: 6 | Pages: 969-974

10.1002/ana.25622 | PMID 31621939 Get It

Accurate antemortem diagnosis of parkinsonism is primarily based on clinical evaluation with limited biomarkers. We evaluated the diagnostic utility of quantitative rapid eye movement (REM) sleep without atonia analysis in the submentalis and anterior tibialis muscles in parkinsonian patients (53 synucleinopathy, 24 tauopathy). Receiver operating characteristic curves determined REM sleep without atonia cutoffs distinguishing synucleinopathies from tauopathies. Elevated submentalis muscle activity was highly sensitive (70–77%) and specific (95–100%) in distinguishing synucleinopathy from tauopathy. In contrast, anterior tibialis synucleinopathy discrimination was poor. Our results suggest that elevated submentalis REM sleep without atonia appears to be a potentially useful biomarker for presumed synucleinopathy etiologies in parkinsonism. ANN NEUROL 2019;86:969–974
Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Parikh, Kejal , Abouzaid, Safiya, Zhou, Zhou , Clancy, Zoe, Cheung, Claudia , Zhou, Zheng‐Yi , Xie, Jipan , Ailawadhi, Sikander , Tang, Wenxi

Mayo Clinic

Blood Advances | October 17, 2019 | Volume: 3 | Issue: 20 | Pages: 2986-2994

10.1182/bloodadvances.2019000308 | PMID 31648322 Get It

Abstract The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and End Results (SEER)–Medicare (2007-2013) database were included. Continuous Medicare enrollment for 6 months before (baseline) and after MM diagnosis was required unless death occurred. Time from MM diagnosis to novel therapy initiation and autologous stem cell transplant (ASCT), overall survival (OS), and MM-specific survival (MSS) was evaluated. Unadjusted and multivariable regressions compared African Americans and Hispanics vs whites. Trends of novel therapy and ASCT use across MM diagnosis years were assessed using linear regression models. The study included 3504 whites, 858 African Americans, and 468 Hispanics. African Americans and Hispanics had a longer time from MM diagnosis to novel therapy initiation vs whites (median: 5.2 and 4.6 vs 2.7 months, respectively). All cohorts had an increasing trend of novel therapy initiation within 6 months of MM diagnosis, particularly whites (all P &lt; .05). Median MSS was significantly longer for African Americans (5.4 years) than whites (4.5 years; P &lt; .05), and was comparable for Hispanics and whites. Median OS was similar overall (2.6-2.8 years). ASCT rate within 1 year of MM diagnosis rose among whites and African Americans (P &lt; .05), but not Hispanics, who were less likely to receive ASCT vs whites. Significant variations in novel therapy and ASCT use were observed among different racial/ethnic groups with MM. Although OS was similar, both African Americans and Hispanics may not be fully benefitting from the introduction of novel therapies, as they receive them later than whites.
Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease—A Cross Sectional Study
Milovanovic, Tamara, Dragašević, Sanja , Zgradić, Sanja, Miličić, Biljana , Dumic, Igor , Kmezić, Stefan , Šaponjski, Dušan , Antić, Andrija , Marković, Velimir , Alempijević, Tamara , Saponjski, Dusan , Alempijevic, Tamara , Dumic, Igor , Lalošević, Milica Stojković , Popović, Dragan

Mayo Clinic

Medicina | October 17, 2019 | Volume: 55 | Issue: 10 | Pages: 697

10.3390/medicina55100697 | PMID 31627351 Get It

Background and Objectives: The aim of the study was to determine the association between presences of fatty pancreas (FP) with the features of metabolic syndrome (MeS) in patients with non–alcoholic fatty liver disease (NAFLD) and to establish a new noninvasive scoring system for the prediction of FP in patients with NAFLD. Material and Methods: 143 patients with NAFLD were classified according to FP severity grade into the two groups and evaluated for diagnostic criteria of MeS. All patients underwent sonographic examination with adiposity measurements and the liver biopsy. Liver fibrosis was evaluated semi-quantitatively according to the METAVIR scoring system and using non-invasive markers of hepatic fibrosis. Results: Waist circumference (WC) was predictive for increased risk of FP in NAFLD patients. Elevated fasting plasma glucose, total cholesterol, serum amylase and lipase levels were associated with presence of severe FP (p value = 0.052, p value = 0.007, p value = 0.014; p value = 0.024, respectively). Presence of increased amounts of mesenteric fat was associated with severe FP (p value = 0.013). The results of this study demonstrated highly significant association between NAFLD and presence of FP. The model for predicting the presence of FP was designed with probability value above 6.5. Conclusion: Pancreatic fat accumulation leads to worsening of pancreatic function which in turns exacerbates severity of metabolic syndrome associated with both, NAFLD and NAFPD.
Acute Kidney Injury after Lung Transplantation: A Systematic Review and Meta-Analysis
Lertjitbanjong, Ploypin , Cheungpasitporn, Wisit , O’Corragain, O.A., Srivali, Narat , Watthanasuntorn, Kanramon , Aeddula, Narothama Reddy , Salim, Sohail Abdul , Ungprasert, Patompong , Gillaspie, Erin A. , Mao, Michael A. , Kaewput, Wisit , Cheungpasitporn, Wisit , Aeddula, Narothama Reddy , Ungprasert, Patompong , Mao, Michael A , Kaewput, Wisit , Srivali, Narat , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

Journal of Clinical Medicine | October 17, 2019 | Volume: 8 | Issue: 10 | Pages: 1713

10.3390/jcm8101713 | PMID 31627379 Get It

Background: Lung transplantation has been increasingly performed worldwide and is considered an effective therapy for patients with various causes of end-stage lung diseases. We performed a systematic review to assess the incidence and impact of acute kidney injury (AKI) and severe AKI requiring renal replacement therapy (RRT) in patients after lung transplantation. Methods: A literature search was conducted utilizing Ovid MEDLINE, EMBASE, and Cochrane Database from inception through June 2019. We included studies that evaluated the incidence of AKI, severe AKI requiring RRT, and mortality risk of AKI among patients after lung transplantation. Pooled incidence and odds ratios (ORs) with 95% confidence interval (CI) were obtained using random-effects meta-analysis. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42019134095). Results: A total of 26 cohort studies with a total of 40,592 patients after lung transplantation were enrolled. Overall, the pooled estimated incidence rates of AKI (by standard AKI definitions) and severe AKI requiring RRT following lung transplantation were 52.5% (95% CI: 45.8–59.1%) and 9.3% (95% CI: 7.6–11.4%). Meta-regression analysis demonstrated that the year of study did not significantly affect the incidence of AKI (p = 0.22) and severe AKI requiring RRT (p = 0.68). The pooled ORs of in-hospital mortality in patients after lung transplantation with AKI and severe AKI requiring RRT were 2.75 (95% CI, 1.18–6.41) and 10.89 (95% CI, 5.03–23.58). At five years, the pooled ORs of mortality among patients after lung transplantation with AKI and severe AKI requiring RRT were 1.47 (95% CI, 1.11–1.94) and 4.79 (95% CI, 3.58–6.40), respectively. Conclusion: The overall estimated incidence rates of AKI and severe AKI requiring RRT in patients after lung transplantation are 52.5% and 9.3%, respectively. Despite advances in therapy, the incidence of AKI in patients after lung transplantation does not seem to have decreased. In addition, AKI after lung transplantation is significantly associated with reduced short-term and long-term survival.
Deleterious mtDNA mutations are common in mature oocytes
Hayama, Tomonari , Dyken, Crystal Van , Darby, Hayley, Koski, Amy , Lee, Yeonmi , Gutiérrez, Nuria Martí , Li, Ying , Andrews, Michael, Ahmed, Riffat, Liang, Dan , Gonmanee, Thanasup , Kang, Eunju , Nasser, Mohammed , Kempton, Beth, Brigande, John V. , McGill, Trevor J. , Amato, Paula, Mitalipov, Shoukhrat , Yamada, Satsuki , Ma, Hong , Terzic, André

Mayo Clinic

Biology of Reproduction | October 17, 2019 | Volume: 102 | Issue: 3 | Pages: 607-619

10.1093/biolre/ioz202 | PMID 31621839 Get It

Abstract Heritable mitochondrial DNA (mtDNA) mutations are common, yet only a few recurring pathogenic mtDNA variants account for the majority of known familial cases in humans. Purifying selection in the female germline is thought to be responsible for the elimination of most harmful mtDNA mutations during oogenesis. Here we show that deleterious mtDNA mutations are abundant in ovulated mature mouse oocytes and preimplantation embryos recovered from PolG mutator females but not in their live offspring. This implies that purifying selection acts not in the maternal germline per se, but during post-implantation development. We further show that oocyte mtDNA mutations can be captured and stably maintained in embryonic stem cells and then reintroduced into chimeras, thereby allowing examination of the effects of specific mutations on fetal and postnatal development.